ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0  AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Session date: 
Friday, May 8, 2020 - 8:00am to 9:00am
Location: 
WebEx meeting
Milwaukee, WI 53226
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Target audience: 
  • Physicians
  • Allied Health Care Professionals
Learning objectives: 
  • To understand the detrimental impact of progressive ILD on morbidity and mortality. Be able to recognize the signs, symptoms of systemic sclerosis related interstitial lung disease. 

  • Be able to screen for SSc and ILD, monitor disease progression, and have an appropriate treatment plan to prevent disease progression and death. 

  • To undertake a screening history for ILD or for subtle features of SSc. To understand the importance of shared decision-making on treatment adherence and anticipatory guidance on preventing co-morbidities and complications. 

 

Faculty & credentials: 

Course Director: Mike Frank, MD

Presenter:

Lesley Ann Saketkoo, MD, MPH

Associate Professor of Medicine

Louisiana State University and Tulane University Schools of Medicine;

Adjunct Professor at Tulane Department of Honors

Director, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships.  These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
 

Dr. Saketkoo has the following financial relationships to disclose.

Commercial Interest 

Nature of Relevant Financial Relationship 

(Include all those that apply) 

What was received 

For What Role? 

Example: Company ‘X’ 

Honorarium 

Speaker 

Boerhinger Ingelheim 

Honorarium 

Speaker 

Unitied Pharamceuticals 

Research Funds 

Investigator 

EICOS Phrmaceuticals 

Fee 

Consultancy 

 

 

 

Contact

Name: 
Kathy A. Rafel
Phone number: 
+1 (414) 955-0531